More Americans have received at least one dose of COVID-19 vaccine than tested positive for the virus, an early but hopeful milestone in the race to end the pandemic.
According to data collected by the Bloomberg Vaccine Tracker, 26.5 million Americans had received one or both doses of the current vaccines as of Monday afternoon. Since the first American patient tested positive outside of Seattle a year ago, 26.2 million people in the country have tested positive for the disease and 441,000 have died, according to data from Johns Hopkins University.
According to data collected by Bloomberg, the US is delivering injections faster than any country in the world every day, at about 1.35 million doses per day. While the rollout stumbled at first, in the six weeks since the first shots were fired in the arms, nearly 7.8% of Americans have received one or more doses and 1.8% have been fully vaccinated.
“It’s worth noting that today, for the first time, the data shows that more people have been vaccinated than reported as newly diagnosed cases,” said Paula Cannon, professor of microbiology at the University of Southern California’s Keck School of Medicine. ‘That’s worth celebrating. I’m all for that victory. ‘
Only a few other countries have passed that milestone: Israel, the UK and the UAE beat the US days or weeks ago for tending to have more vaccinations than cases.
After a holiday spate of U.S. cases, officials at the Center for Disease Control and Prevention are calling the summit, though that’s likely due to behavioral changes and still no widespread impact from the vaccine. New COVID-19 cases, hospitalizations and emergency room visits are beginning to decline, said Jay Butler, the deputy director of the Infectious Diseases Bureau.
“While these trends are encouraging, I would like to emphasize that the numbers are still high nationally, and they are as high as they have been during the pandemic so far,” he said during a briefing on Friday hosted by the Infectious. Diseases Society of America. “If this pandemic was a stock, we might want to sell.”
The virus can still roar, especially if variants emerging in South Africa and elsewhere emerge. Studies suggest that vaccines, especially the newer injections from Johnson & Johnson and Novavax Inc., are less potent against that species and at least one other.
The goal is to eventually achieve herd immunity, when so many Americans have protection thanks to a vaccine or natural infection, the virus struggles to spread, and eventually dies. Public health officials, including Dr. Anthony Fauci, the nation’s top infectious disease physician, estimates that 70% to 85% of the 330 million Americans must be exposed to the pathogen through a virus or vaccine to reach that level.
While a past infection can create immunity, it’s not clear how long it lasts. And it takes not only deaths, but hundreds of thousands of hospitalizations, and some reporting persistent illness and a bewildering array of symptoms, including fatigue, depression, and difficulty breathing.
“There is a price to pay in suffering and in costs to the health system,” said Alessandro Sette, a professor at the La Jolla Institute for Immunology. “It’s long-lasting and serious.”
Meanwhile, no deaths have been definitively associated with receiving a COVID-19 vaccine. The U.S. Food and Drug Administration’s voluntary adverse event tracking system includes reports of approximately 290 deaths from the administration of a coronavirus vaccine on Jan. 22. Most were in the elderly with other health conditions and none were determined to be bound to the immunizations.
Questions persist. It is still not clear exactly how many people have been vaccinated or infected, and it may never be. Many more people have had the virus than tested positive, especially those with mild or asymptomatic cases.
Reported vaccinations are also lower than the number actually given because people are more focused on injecting into weapons than putting the data into tracking systems, Cannon said. It takes two shots for full immunity, which only 5.82 million Americans received.
It’s still early days in the immunization effort, which has been plagued by a lack of coordination, confusion over who should have access, and a shortage of supply, which has reduced the number of people who were able to receive the shot in the first weeks of the rollout diminished.
It’s also important to make sure the right people are immunized to get the most benefit, said Bill Moss, executive director of Johns Hopkins University’s International Vaccine Access Center.
“There are many people who get vaccinated who do not fall into the risk categories,” he said. “If that is the case, it will take longer for the number of serious illnesses and deaths to decline. Everyone needs a vaccine at some point, but I am concerned about the inequalities in the way the system has been rolled out.”
The emerging variants have created a new urgency to increase vaccination rates, said Daniela Weiskopf, a research assistant professor at the La Jolla Institute for Immunology. Every time the virus replicates, there is a chance that a variant will emerge.
“The sooner we interrupt this, the more likely we will not see more variants appear,” she said.
© Copyright 2021 Bloomberg News. All rights reserved.